©The Author(s) 2026.
World J Gastrointest Oncol. Jan 15, 2026; 18(1): 113440
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.113440
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.113440
Table 3 Comparison of objective response rate and disease control rate between the two groups, n (%)
| Healing effect | Total number of cases (n = 126) | CMT group (n = 87) | CMT + ICI group (n = 39) | P value |
| ORR | 88 (69.8) | 51 (58.6) | 37 (94.9) | < 0.001 |
| DCR | 104 (82.5) | 65 (74.7) | 39 (100.0) | < 0.001 |
- Citation: Dai EH, Que SH, Xu H, Zhong GQ, Zhang Z, Liang X, Zhai SW, Li YT, Wang JJ, Feng W. Efficacy and safety of immune checkpoint inhibitors plus chemotherapy in esophageal cancer patients with liver metastases. World J Gastrointest Oncol 2026; 18(1): 113440
- URL: https://www.wjgnet.com/1948-5204/full/v18/i1/113440.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v18.i1.113440